金秋时节,康希诺生物,两款疫苗,同日启程。优佩欣®(PCV13i)国内首发,为中国儿童带来更优保护;曼海欣®(MCV4)迈出国门,践行“世界无疫”的担当。9月29日,康希诺生物自主研发的13价肺炎球菌多糖结合疫苗优佩欣®(PCV13i)和亚洲首款四价流脑多糖结合疫苗曼海欣®(MCV4)分别发往国内和海外市场,标志着公司立足高质量创新产品不断取得新的成就,也为未来拓展国际化商业布局迈出重要一步。...
Source Link金秋时节,康希诺生物,两款疫苗,同日启程。优佩欣®(PCV13i)国内首发,为中国儿童带来更优保护;曼海欣®(MCV4)迈出国门,践行“世界无疫”的担当。9月29日,康希诺生物自主研发的13价肺炎球菌多糖结合疫苗优佩欣®(PCV13i)和亚洲首款四价流脑多糖结合疫苗曼海欣®(MCV4)分别发往国内和海外市场,标志着公司立足高质量创新产品不断取得新的成就,也为未来拓展国际化商业布局迈出重要一步。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.